ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2110

Association Between Symptomatic Knee Osteoarthritis and Blood Glucose Control in Persons with Type 2 Diabetes

Lauren King1, Alanna Weisman1, Baiju Shah1, Robert Goldberg1, Amish Parikh2, Ian Stanaitis3, Rosane Nisenbaum4, Esther Waugh1, Lorraine Lipscombe1 and Gillian Hawker1, 1University of Toronto, Toronto, ON, Canada, 2Trillium Health Partners, Toronto, ON, Canada, 3Women's College Hospital, Toronto, ON, Canada, 4Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, ON, Canada

Meeting: ACR Convergence 2024

Keywords: Comorbidity, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Osteoarthritis – Clinical Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: There is a high prevalence of knee osteoarthritis (OA) in people with type 2 diabetes (T2D), and knee OA increases risk for diabetes complications and cardiovascular events. Potential mechanisms linking symptomatic knee OA to worse outcomes in T2D include the effects of OA-related pain and immobility on blood glucose control and cardiorespiratory fitness, and systemic inflammation. Our objective was to assess the association between symptomatic knee OA and attainment of target blood glucose levels in individuals with T2D.

Methods: In this cross-sectional study, we recruited individuals with T2D aged ≥45 years from diabetes clinics at three academic hospitals in Toronto, Canada. Participants completed standardized online questionnaires that assessed demographics, comorbidities, height and weight, and joint symptoms. From clinic records we abstracted participants’ most recent HbA1c (within 3 months of questionnaire completion). Knee OA was defined as fulfilling NICE criteria (activity-exacerbated knee pain, morning joint stiffness ≤ 30 minutes) without diagnosis of inflammatory rheumatic disease. We considered diabetes blood glucose control at target if HbA1c was ≤7.0%. We used multivariable logistic regression to assess the association between knee OA and being at blood glucose target, adjusting for age and gender. We then examined the effect of further adjusting for body mass index (BMI), a risk factor for and consequence of knee OA. In secondary analyses, to understand effects in individuals who reported at least a mild average level pain over the past week, we repeated modelling with exposure of interest knee OA with knee pain ≥20/100 on pain numeric rating scale (NRS) (yes/no).

Results: We included 351 participants. Mean age was 66.9 (SD 9.8) years, 50.7% women, 81.1% had a post-secondary education, mean BMI 29.1 (SD 6.8) kg/m2, and 28.5% fulfilled NICE criteria for knee OA. Mean HbA1c was 7.4 (SD 1.2); 44% had HbA1c at target (≤7.0%) (Table 1). In univariable analysis, those with knee OA had lower odds of being at target (OR 0.60, 95% CI 0.37 to 0.97). Results were similar after adjusting for age and gender (OR 0.59, 95% CI 0.36 to 0.95). When further adjusting for BMI the effect of knee OA was attenuated and was not statistically significant (OR 0.65, 95% CI 0.39 to 1.06) (Figure 1). When exposure of interest was knee OA with self-reported pain ≥20/100, we found a stronger negative association; this met statistical significance even after adjusting for BMI (OR 0.59, 95% CI 0.35 to 0.997) (Figure 2).

Conclusion: Individuals with T2D with knee OA are less likely to be at the recommended target for glycemic control. This association was stronger for those who currently reported pain and remained significant even after adjusting for BMI. This suggests that symptomatic knee OA may increase risk of diabetes complications through worse glycemic control, and symptom severity is likely important. Future prospective studies with larger sample sizes are needed to better understand this relationship, as well as the role of additional mechanisms by which knee OA could lead to diabetes complications such as cardiorespiratory fitness and/or systemic inflammation.

Supporting image 1

Supporting image 2

Model 1: univariable
Model 2: adjusted for age, gender
Model 3: adjusted for age, gender, BMI

Supporting image 3

Model 1: univariable
Model 2: adjusted for age, gender
Model 3: adjusted for age, gender, BMI


Disclosures: L. King: None; A. Weisman: None; B. Shah: None; R. Goldberg: None; A. Parikh: None; I. Stanaitis: None; R. Nisenbaum: None; E. Waugh: None; L. Lipscombe: None; G. Hawker: None.

To cite this abstract in AMA style:

King L, Weisman A, Shah B, Goldberg R, Parikh A, Stanaitis I, Nisenbaum R, Waugh E, Lipscombe L, Hawker G. Association Between Symptomatic Knee Osteoarthritis and Blood Glucose Control in Persons with Type 2 Diabetes [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/association-between-symptomatic-knee-osteoarthritis-and-blood-glucose-control-in-persons-with-type-2-diabetes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-symptomatic-knee-osteoarthritis-and-blood-glucose-control-in-persons-with-type-2-diabetes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology